Multicenter phase 1b trial of intratumoral oncolytic virus V937 plus ipilimumab for advanced melanoma
Dr. Brendan Curti
The multicenter phase 1b MITCI trial in the United States found that intratumoral oncolytic virus V937 in combination with intravenous ipilimumab (anti-CTLA-4) for advanced melanoma induced robust responses, including in the subgroup of patients who had experienced disease progression on prior anti-PD-1 therapy. Objective response rate was 30% (95% CI 18-45) among all treated patients, 47% (23-72) among patients who had not received prior anti-PD-1 therapy, and 21% (9-39) among patients who had experienced disease progression on prior anti-PD-1 therapy. Toxicities were manageable.
